Oral mucositis is a dose-limiting toxicity of intensive chemotherapy. It is caused directly by the cytotoxic effect of chemotherapeutic agents and indirectly by sustained neutropenia. Severe oral mucositis is an important predisposing factor for life-threatening septic complications during aplasia. It also reduces quality of life. At present, no effective causal prophylaxis or treatment against oral mucositis is established. We performed a prospective randomised placebo-controlled trial using topical oral r-metHuG-CSF (filgrastim) in highgrade lymphoma patients treated according to the B-NHL protocol, which contains high-dose methotrexate and causes severe oral mucositis (WHO grades I-IV) in Ͼ50% of patients. Between August 1996 and July 1997, a total of 32 chemotherapy cycles were documented in eight patients (four male, four female). Mucosal erythema and ulceration were recorded. All patients assessed their oral pain and impact on swallowing daily, using a subjective scale from no to maximal discomfort (1-10). In addition, oral mucositis was assessed according to the WHO score. Filgrastim was administered in 16 cycles as a viscous mouthrinse (carboxymethylcellulose 2%, oleum citrii) 4 × 120 g/day from days 10 to 16. Sixteen cycles were given to control patients, of these 14 with placebo, and another two cycles with no treatment. Severe mucositis (WHO grade III/IV) was documented in 21 of 32 cycles (65.5%). A difference of borderline significance was observed for the reduction of maximum severity of oral mucositis between G-CSF vs placebo (P = 0.058), with a reduction of WHO grade IV of 50% (four G-CSF vs eight control). The number of days in hospital was reduced significantly in the G-CSF group (P = 0.02). In conclusion, topical oral G-CSF mouthrinses may be beneficial to reduce oral mucositis. Keywords: oral mucositis; topical G-CSF; high-grade lymphoma; randomised trial Oral mucositis is a major side-effect of chemotherapy. It occurs with an incidence of about 40%.
oral mucositis include cytotoxic effects of chemotherapeutic agents, decrease of neutrophils in the oral cavity, dental trauma and infection. 3 The oral mucosa is susceptible to the toxic effects of chemotherapeutic agents due to its high mitotic index. Oral mucositis starts usually 5-7 days after the onset of the chemotherapy and first presents with an erythema followed by ulceration, ranging from aphthous-like lesions to generalised desquamation. Normal mucosa acts as a barrier against the ever present oral microorganisms. The disruption of this mucosal barrier can lead to infections, 4, 5 increased pain and decreased nutrition. Severity and extent of mucositis vary with the cytotoxic drugs used, mode of application, and extent of myelosuppression. 6, 7 Certain chemotherapeutic agents, eg 5-fluorouracil and high-dose methotrexate are commonly associated with the development of oral mucositis. 8 Most studies to date have focused on the prevention or therapy of 5-fluorouracil-induced mucositis. 9, 10 No longitudinal studies have documented the onset and development of ulcerative mucositis in patients treated with high-dose methotrexate according to the B-NHL93 protocol. 11 Although children and adults are known to be affected by oral mucositis WHO grades I-IV in regimens containing high-dose methotrexate in up to 53% of cases, 11, 12 no effective therapy has been established. Currently, therapy aims to effect pain relief and prevent bacterial and fungal complications.
It is well known that healing of mucositis is associated with neutrophil recovery. However, the relationship between the neutrophil count in the oral cavity and the occurrence of mucositis is not completely understood. Lieschke et al 13 found that the neutrophil count in oral mouth rinses recovered 1-3 days prior to the increase of the circulating neutrophil count above 0.1 × 10 9 /l in patients receiving high-dose chemotherapy and bone marrow transplantation. Additionally, studies using subcutaneous G-CSF or GM-CSF showed a beneficial effect on oral mucositis which was explained by a shortened period of neutropenia.
14-17 G-CSF is known to stimulate migration, phagocytosis and cytotoxicity of neutrophils. 18 We postulated an effect of topical oral G-CSF on neutrophils in the oral cavity as a rationale for this study.
All patients were treated according to the B-NHL93 protocol. Therefore, data on the incidence of ulcerative mucositis, duration of lesions, and the relationship of oral mucositis to known risk factors, such as dose of methotrexate, and severity as duration of neutropenia could be obtained. Specifically, we studied the influence of topically applied G-CSF on severity of oral mucositis in these patients in the absence of systemic G-CSF. In addition, the influence of topical oral G-CSF on days in hospital, in relation to the need and duration for opioid therapy, and incidence and days of febrile neutropenia were studied.
Patients and methods
Patients enrolled in this study had a diagnosis of high-grade malignant lymphoma (stages II-IV) and were treated according to the B-NHL93 protocol. They were 18-65 years of age, and were judged to have good compliance.
Exclusion criteria were pregnancy or lactation, known neoplasms of the upper gastrointestinal tract or CNS, manifest mental illness, history of non-compliance, latent or manifest renal failure (serum creatinine Ͼ1.5 mg/dl; creatinine clearance Ͻ50 ml/min), cranial irradiation, and systemic use of G-CSF. Furthermore, patients were excluded who presented with oral lesions, proven bacterial or fungal infection of the oral cavity or oropharynx at the start of therapy, severe infections requiring intravenous antibiotics during the previous 14 days, and necessity for opioid medication at study entry. All patients gave written informed consent according to the institutional guidelines before enrollment.
Patients
From August 1996 to July 1997 eight patients with highgrade lymphoma (Ki-1 lymphoma, n = 3; large cell B-NHL, n = 3; Burkitt-lymphoma, n = 1; T cell-rich B-NHL, n = 1) were treated with 32 cycles of chemotherapy according to the B-NHL93 protocol, which consists of three cycles of protocol A and three cycles of protocol B given alternatively.
Protocol A was vincristine 2 mg + high-dose methotrex- 
Study medication
Before starting the study we tested different concentrations of viscous mouthrinses on five healthy volunteers. A viscous mouthrinse based on an aequeous carboxymethylcellulose solution (2%) was prepared for the study as follows: carboxymethylcellulose sodium 0.1 g; r-metHuG-CSF (filgrastim) 120 g 0.4 ml; oleum citrii gtt. I; purified water 5.0 ml.
In the placebo medication filgrastim was exchanged for 0.4 ml purified water.
Study design
For this prospective placebo-controlled trial patients were randomly assigned prior to each cycle to receive G-CSF or placebo. Study medication was given unblinded from days +10 to +16 after start of chemotherapy. The rationale for the timing of study medication was an observation of Lieschke et al, 13 who observed neutrophils in oral mouth rinses 1-3 days prior to an increase of the blood neutrophil count following myeloablative chemotherapy. Recovery from neutropenia in patients treated according to the B-NHL protocol was estimated 13-18 days from the onset of chemotherapy.
Study medication was given four times daily (at morning, midday, after evening meals, and at night before sleeping). Each patient was instructed to rinse vigorously with the viscous solution for approximately 1 min, and to avoid food-intake during the next hour.
In addition to the WHO grading system for mucositis, a refined scoring system was used including subjective and objective criteria. Each patient judged oral pain and its impact on swallowing on a subjective scale from 1 (no pain or impact on swallowing) to 10 (maximum pain or impact on swallowing) in a diary in addition. Nine anatomical locations in the mouth (1, upper lip; 2, lower lip; 3, right cheek; 4, left cheek; 5, tongue; (lateral and ventral) right, 6, tongue (lateral and ventral) left; 7, floor of mouth; 8, soft palate/fauces; 9, hard palate/gingiva were inspected regarding severity of erythema (0 = none/normal, 1 = not severe, 2 = severe ) and the presence and size of ulceration (0 = no lesion, 1 = lesion Ͻ1 cm 2 ; 2 = lesion 1-3 cm 2 ; 3 = lesion Ͼ3 cm 2 ). A cumulative mucositis score was calculated for erythema, and ulceration, respectively.
Starting with the first day of chemotherapy, assessment of mucosal status was performed three times weekly and intensified to daily inspection, if first signs of mucositis appeared.
Duration of periods with fever, days on opioid analgesics, and overall stay in hospital were documented for each chemotherapy cycle.
Statistical analysis
Healing of mucositis was defined as a cumulative erythema score р5, and a cumulative ulceration score р5 in the oral cavity. In addition, a dysphagia score р3, and oral pain score р3 had to be documented with none of the four mucositis parameters (erythema, ulceration, pain and dysphagia) in excess, to enable statistical analysis. Start of regeneration was defined as a definitive defervescense in the refined mucositis score regarding pain, dysphagia, erythema and ulceration. Healing curves for patients assigned to the G-CSF and the placebo arm were determined according to the method of Kaplan The study aimed at detecting a reduction in maximum severity of mucositis of 25% between the two treatment arms with a power of 80% at a significance level of P = 0.05 (assuming a standard deviation of one WHO score point). The study was closed after reaching the prospectively planned number of treatment cycles.
Results
From August 1996 to July 1997, 32 chemotherapy cycles in eight patients with high-grade lymphoma were documented. They were randomly assigned to oral G-CSF (n = 16) or the control group (n = 16), the latter including 14 placebo cycles and two cycles without study medication. Both groups were well balanced with respect to age, sex, weight, duration as severity of neutropenia, number of cycles (A/B), methotrexate dose, and methotrexate plasma levels (Table 1) . No correlation was found between the methotrexate dose and severity of oral mucositis (Figure 1 ) or the number of chemotherapy cycles and the severity of mucositis (P = 0.5).
Course of mucositis
Data for the refined scoring system showed erythema as the first sign of oral mucositis. This was observed at day 4.1 (s.d. Ϯ 1.6; range 2-8 days) from onset of chemotherapy (Table 2) . After a mean of 5.7 days (s.d. Ϯ 2.7; range 2-10 days), the first subjective signs of mucositis were noted by the patients as mucosal tension or burning located buccally and labially. Oral ulceration was recorded at day 7.3 (s.d. Ϯ 1.6, range 5-11 days). Patients reported dysphagia on day 8.3 (s.d. Ϯ 3.3; range 2-14 days). In cases of oral mucositis, data from the refined mucositis score verified that buccal and labial mucosa were affected No significant differences were found between the treatment groups. 
Effect of G-CSF on oral mucositis
As shown in Table 3 , WHO grades III/IV mucositis were found in 12 out of 16 episodes in the control arm (75%), but in only nine out of 16 G-CSF cycles (56%). There was a reduction in maximum severity of oral mucositis of borderline significance (P = 0.058). Complete mucosal regeneration needed a median of 18 days after onset of chemotherapy, with no significant difference between the G-CSF and placebo group (P = 0.18, one-sided Peto-Wilcoxon test). However, 20 days after start of chemotherapy, healing was seen in 100% of G-CSF cycles (n = 16), but only in 11 of 14 cases (80%) of placebo cycles. Detailed analysis of the average incidence of oral mucositis per cycle with the refined mucositis score with respect to healing of erythema and ulceration, or improvement of pain and dysphagia, respectively, showed a uniform trend in favour of G-CSF, although it did not reach significance.
Secondary effects of G-CSF on oral mucositis
Duration of hospitalization was shortened significantly in the G-CSF group (18.8 days vs 22.2 days; P = 0.02) ( Table  4) . Fever was documented in three cycles with G-CSF Table 2 Onset, maximum and start of regeneration of oral mucositis (n = 30 cycles). Data were obtained with the refined mucositis score
Mucositis parameter
Onset ( application vs eight febrile episodes in the control group (P = 0.06). The need for opioid therapy was reduced in the G-CSF group by 50%. In addition, the days on opioid therapy were reduced (2.5 days vs 4.6 days; P = 0.21).
Discussion
The overall incidence of oral mucositis grades III/IV was 65.6% in patients treated according to the B-NHL protocol. This emphasizes the need for efficient supportive care in these patients. The observed incidence of mucositis WHO grades III/IV was considerably higher than previously reported in children (8%), 12 and adults treated according to the B-NHL86 protocol (20%). 11 However, the methotrexate dose in our patients was considerably higher than that in the two studies cited above (р1500 mg/m 2 vs 3000 mg/m 2 ).
11,12
The onset and development of oral mucositis was comparable in the G-CSF and the control group. This can be explained by the fact that mucositis is induced by chemotherapeutic agents that were administered equally in both treatment groups. WHO grades III/IV mucositis occurred, however, less frequently in the G-CSF group. In only four out of 16 episodes with G-CSF, was WHO grade IV mucos- Table 4 Effects of oral mucositis on the incidence and duration of fever, need and days of opioids therapy, and days in hospital In addition, the G-CSF patients recovered earlier from mucositis (100% vs 80% at day 20, P = 0.22). This effect is possibly due to local activation of neutrophils by G-CSF, since it is well known that G-CSF stimulates migration, phagocytosis, and cytotoxicity of neutrophils, 18 the precise mechanism, however, being unknown. Additionally, G-CSF may exert an effect on epithelial cell proliferation of the oral mucosa. In animal models it has been shown that the epithelial basal proliferation rate is one of the key elements in determining mucosal sensitivity to cancer chemotherapy. 3 The present treatment of mucositis is symptom-orientated, with a need for opioids in severe cases. There was a 50% reduction in the need for opioids with a reduction in the days on opioids (2.5 vs 4.6 days; P = 0.21). Furthermore, the incidence of fever (three vs eight cycles) was reduced in the G-CSF group by about 62%, with a reduction of duration of fever of borderline significance (P = 0.06). Finally, days in hospital (18.8 vs 22.2 days) were reduced significantly with G-CSF (P = 0.02). We believe that this was due to the earlier resolution from less severe mucositis in the G-CSF group. Severe oral mucositis (WHO уIII) has an important impact on the timing of subsequent chemotherapy cycles (WHO grade рII vs WHO grade уIII; P = 0.0001). Mucositis WHO grade уIII was observed less frequently in the G-CSF group (P = 0.058). In comparison to patients with less severe oral mucositis (WHO grade рII), healing of oral mucositis WHO grade уIII was observed on average 5 days later (day 15 vs day 20). In addition, the incidence of neutropenic fever, which was observed more frequently in patients treated with placebo may play an important role in the difference in duration of hospitalization.
Cartee et al 21 treated breast cancer patients for oral mucositis with topical GM-CSF in a liquid mouthrinse (albumin/water mixture). They did not observe a reduction in the maximum severity of mucositis between placebo and GM-CSF. Since biological responses to growth factors are regulated by the concentration of receptors present in the local environment, perhaps the viscous nature of G-CSF solution used in our study had a more favorable effect on oral mucositis.
In summary, topical application of G-CSF appears to be beneficial with respect to incidence and course of methotrexate-induced mucositis and associated complications. Further studies are required to further elucidate whether earlier institution of this approach can enhance the effects of this haematopoietic growth factor.
